Compare NISN & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NISN | NXL |
|---|---|---|
| Founded | 2005 | 2010 |
| Country | China | United States |
| Employees | N/A | 7 |
| Industry | Metal Fabrications | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.4M | 20.1M |
| IPO Year | 2016 | 2022 |
| Metric | NISN | NXL |
|---|---|---|
| Price | $3.60 | $1.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 15.1K | ★ 261.4K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.43 | N/A |
| Revenue | ★ $340,219,546.00 | $156,931.00 |
| Revenue This Year | N/A | $38.28 |
| Revenue Next Year | N/A | $185.71 |
| P/E Ratio | $15.58 | ★ N/A |
| Revenue Growth | ★ 8.05 | N/A |
| 52 Week Low | $3.22 | $0.70 |
| 52 Week High | $9.33 | $4.49 |
| Indicator | NISN | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 40.00 | 42.46 |
| Support Level | $3.58 | $0.93 |
| Resistance Level | $3.82 | $1.12 |
| Average True Range (ATR) | 0.20 | 0.10 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 0.00 | 35.20 |
NiSun International Enterprise Development Group Co Ltd is a provider of supply chain solutions and integrated financial services. Nisun is dedicated to providing professional supply chain solutions to Chinese and foreign enterprises and financial institutions. Through its subsidiaries, it is engaged in delivering supply chain solutions, and supply chain trading services to its customers across different industries. The company also provides financial solutions to small and mid-sized enterprises within the supply chain ecosystem. Using its fintech platforms, it provides various financing options, including supply chain financing, trade financing, and receivables financing. Geographically, its operations are predominantly focused on markets within the People's Republic of China.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.